Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep;158(3):892-895.
doi: 10.1016/j.chest.2020.04.033. Epub 2020 Apr 29.

When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic

Nadera J Sweiss  1 , Peter Korsten  2 , Huzaefah J Syed  3 , Aamer Syed  3 , Robert P Baughman  4 , Arthur M F Yee  5 , Daniel A Culver  6 , Teresa Sosenko  7 , Arata Azuma  8 , Francesco Bonella  9 , Ulrich Costabel  9 , Wonder P Drake  10 , Marjolein Drent  11 , Elyse E Lower  4 , Dominique Israel-Biet  12 , Remy L M Mostard  13 , Hilario Nunes  14 , Paola Rottoli  15 , Paolo Spagnolo  16 , Athol U Wells  17 , Wim A Wuyts  18 , Marc A Judson  19
Affiliations
Editorial

When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic

Nadera J Sweiss et al. Chest. 2020 Sep.
No abstract available

Keywords: ADA, adalimumab; COVID-19, coronavirus disease 2019; DMASD, disease-modifying antisarcoid drug; GC, glucocorticoid; SARS; coronavirus disease; diffuse lung disease; immunosuppressives; sarcoidosis; severe acute respiratory syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed management algorithm of immunosuppression for sarcoidosis during the COVID-19 pandemic. Our recommended approach for two types of patients is depicted: the clinically stable patient who is in remission with therapy, and the patient with continued, active disease or organ dysfunction requiring continued immunosuppression. Details are given in the text. COVID-19 = Coronavirus Disease 2019; DMASD = disease-modifying antisarcoid drug; GC = glucocorticoid; TNFi = tumor necrosis factor inhibitor.
See this image and copyright information in PMC

Comment in

  • Management Issues of Sarcoidosis in the Time of Coronavirus Disease 2019.
    Tana C, Schiavone C, Cipollone F, Giamberardino MA. Tana C, et al. Chest. 2021 Mar;159(3):1306-1307. doi: 10.1016/j.chest.2020.09.267. Chest. 2021. PMID: 33678261 Free PMC article. No abstract available.
  • Response.
    Sweiss NJ, Korsten P, Baughman RP, Culver DA, Judson MA. Sweiss NJ, et al. Chest. 2021 Mar;159(3):1307-1308. doi: 10.1016/j.chest.2020.10.005. Chest. 2021. PMID: 33678263 Free PMC article. No abstract available.

References

    1. Baughman R.P., Teirstein A.S., Judson M.A. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 pt 1):1885–1889. - PubMed
    1. Grunewald J., Grutters J.C., Arkema E.V., Saketkoo L.A., Moller D.R., Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45. - PubMed
    1. Garg S., Kim L., Whitaker M. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464. - PMC - PubMed
    1. Judson M.A. Corticosteroids in sarcoidosis. Rheum Dis Clin North Am. 2016;42(1):119–135, ix. - PubMed
    1. Doran M.F., Crowson C.S., Pond G.R., O’Fallon W.M., Gabriel S.E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–2300. - PubMed

Publication types

LinkOut - more resources